Read more

February 15, 2023
1 min read
Save

Top in endocrinology: Rise in obesity prevalence; phthalate exposure and diabetes risk

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Despite more adults achieving lipid and BP control between 1999 and 2020, the prevalence of obesity has increased among adults with diabetes in the United States during this period, data show.

In addition, fewer adults with diabetes achieved glycemic control with an HbA1c of less than 7% from 2015 to 2020 compared with 2007 to 2010. It was the top story in endocrinology last week.

Scale and tape measure
Despite more adults achieving lipid and BP control between 1999 and 2020, the prevalence of obesity has increased among adults with diabetes in the United States during this period, data show. Source: Adobe Stock

The second top story was about a study that showed midlife white women who were exposed to some phthalate metabolites had an increased likelihood for developing diabetes. The association was not observed among Black women and Asian women.

Read these and more top stories in endocrinology below:

Prevalence of obesity increasing among US adults with diabetes

The proportion of adults with diabetes and obesity in the U.S. increased from 1999 to 2020, though more adults achieved BP and lipid control during that period, according to a study published in Obesity. Read more.

Phthalate exposure linked to diabetes for midlife white women

Among midlife women participating in a large longitudinal study, certain phthalate metabolites were associated with higher diabetes incidence over 6 years — but only among white women, according to data published in The Journal of Clinical Endocrinology & Metabolism. Read more.

33% of adults with type 2 diabetes lost 5% or more of body weight with GLP-1 agonists

About one-third of adults who were prescribed a GLP-1 receptor agonist to treat type 2 diabetes lost at least 5% of their body weight at 72 weeks, according to findings from a real-world retrospective analysis. Read more.

Glucagon use declines from 2011 to 2021 among adults with diabetes

Fewer people with diabetes filled glucagon prescriptions in 2021 compared with 2011, though increases were seen among those with type 1 diabetes and adults with a history of severe hypoglycemia, according to study data. Read more.

Gender-affirming HT improves appearance congruence for transgender adolescents

Transgender and nonbinary youths had greater appearance congruence — the experience that physical appearance aligns with gender —and less depression and anxiety after 2 years of gender-affirming hormone therapy, according to study data. Read more.